Amarin Corporation plc - American Depositary Shares, each repre — Cash Flow (NASDAQ:AMRN)

Financials

Cash from operating activities -21.75 M-66.54 M-180.09 M6.88 M-31.02 M6.73 M 6.73 M Cash from investing activities -376.96 M104.1 M175.29 M-25.52 M-45.98 M8.83 M 8.83 M Cash from financing activities -58.91 M-5.07 M-379 K230 K-1.44 M-2.03 M -2.03 M Free cash flow -22 M-66.54 M-180.69 M6.37 M-31.02 M6.73 M 6.73 M

Amarin Corporation plc - American Depositary Shares, each repre

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza.

AMRN

Financials

Amarin Corporation plc - American Depositary Shares, each repre

新闻

AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know

Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss

Amarin Corporation plc 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:AMRN) 2026-02-25

New Strong Sell Stocks for January 28th

BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock?

Do Options Traders Know Something About Amarin Stock We Don't?

US Supreme Court to hear ’skinny label’ patent fight involving Amarin

AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations

Amarin强调VASCEPA在新型甘油三酯疗法中的作用

Amarin highlights VASCEPA’s role amid new triglyceride therapies

Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report?

Amarin将在美国心脏协会科学会议上展示VASCEPA新数据